Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07700199

AI-Driven Survivorship Care Plans (AI-SCP)

This project conducts exploratory work on a HIPAA-compliant, large language model (LLM)-based tool that integrates structured and unstructured oncology electronic health record (EHR) data to automate the development of tailored SCPs, paired with a patient-facing chatbot to answer questions about the SCP. Unlike generic AI documentation tools, this system establishes benchmarks for SCP development and embeds user-centered design (UCD) directly into prompt engineering and model governance workflows.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Cancer Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Utah

Salt Lake City, Utah, 84112, United States

Location contact

Echo Warner, MPH, PhD, SB

CONTACT

[email protected]

801-244-7040

Echo Warner, MPH, PhD, SB

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult cancer survivors
  • Age +18 years,
  • Speak and understand English
  • Affiliated with the Huntsman Cancer Institute.

Exclusion criteria

  • Under age 18
  • Not affiliated with Huntsman Cancer Institute
  • Unable to speak or understand English

Treatment and study plan

SCP Chatbot

Other

A secure LLM pipeline with structured and unstructured EHR data to automatically generate Survivorship Care Plans (SCPs) and develop a patient-facing chatbot to support comprehension.

The SCP chatbot will leverage GARDE-Chat, an NCI-funded open-source chatbot platform

Other names: GARDE-Chat

Primary outcomes

  1. Feasibility: Recruitment Retention

    Time frame: up to 7 days

    Feasibility of the interactive AI-SCP and chatbot. This outcome measure will report the proportion of subjects who were retained from recruitment.

Secondary outcomes

  1. Acceptability/Usability: System Usability Scale

    Time frame: up to 7 days

    Acceptability and usability of the interactive AI-SCP and chatbot. This outcome measure will report the mean System Usability Scale (SUS) score. SUS scores range from 0-100, with higher scores indicating better usability and lower scores indicating worse usability.

Other outcomes

  1. Change in PROMIS Anxiety

    Time frame: up to 7 days

    To assess preliminary patient-level effects of the interactive AI-SCP and chatbot. This outcome measure will report mean change in PROMIS Anxiety T-scores.

    PROMIS Anxiety 4a - Adult v1.0 Scores range from 40.3 to 81.6, with lower scores indicating less anxiety and higher scores indicating more anxiety.

  2. Change in Cancer Worry Scale

    Time frame: up to 7 days

    To assess preliminary patient-level effects of the interactive AI-SCP and chatbot. The Cancer Worry Scale (CWS) uses a 4-point Likert scale to measure cancer-related worry. This outcome measure will report the mean change in CWS score.

    CWS scores range from 8 to 32, with lower scores indicating less worry and higher scores indicating greater worry.

Study contacts

Contact information is provided by the study sponsor or research team.

Echo Warner, MPH, PhD, SB

CONTACT

[email protected]

801-244-7040

Sponsors and collaborators

Lead sponsor

University of Utah

Other

Collaborators

  • Huntsman Cancer Institute

Registry information

Acronym: AI-SCP

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 13, 2026
Registry last updated
Jul 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.